Valuation: DMS

Market Cap 27.99M 32.2M 26.05M 23.92M 45.17M 3.07B 45.87M 307M 121M 1.53B 121M 118M 5.13B P/E 2026 *
36x
P/E 2027 * 10.8x
Enterprise Value 43.39M 49.91M 40.39M 37.08M 70.02M 4.76B 71.1M 476M 187M 2.37B 187M 183M 7.95B EV / Sales 2026 *
0.76x
EV / Sales 2027 * 0.55x
Free-Float
69.9%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 18/07/2022
Director of Finance/CFO - 01/01/2022
Chief Tech/Sci/R&D Officer - 01/01/2019
Director TitleAgeSince
Chairman 53 18/07/2022
Director/Board Member 52 16/06/2025
Director/Board Member - 24/07/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 32.2M
-0.84%+5.24%-13.34%-16.71% 14.02B
+4.81%-6.82%+38.55%-12.19% 3.9B
+1.81%+11.70%-36.35%-55.26% 1.27B
+1.98%+9.99%-35.86%-43.67% 1.18B
-4.57%-3.84%+37.31%+102.09% 1.16B
+1.35%+5.63%-45.42% - 952M
+17.03%+10.93%+29.15%+99.38% 500M
-1.79%+1.39%+68.29% - 329M
+0.36%+2.02%-59.27%+221.90% 265M
Average +2.01%+1.42%-1.88%+42.22% 2.62B
Weighted average by Cap. +0.66%+2.16%-4.41%-7.92%

Financials

2026 *2027 *
Net sales 56.8M 65.34M 52.87M 48.54M 91.66M 6.24B 93.08M 623M 245M 3.11B 245M 240M 10.41B 65.9M 75.81M 61.34M 56.32M 106M 7.24B 108M 723M 284M 3.6B 285M 278M 12.08B
Net income 800K 920K 745K 684K 1.29M 87.85M 1.31M 8.78M 3.44M 43.74M 3.46M 3.38M 147M 2.6M 2.99M 2.42M 2.22M 4.2M 286M 4.26M 28.53M 11.2M 142M 11.23M 10.99M 477M
Net Debt 15.4M 17.72M 14.33M 13.16M 24.85M 1.69B 25.24M 169M 66.31M 842M 66.53M 65.07M 2.82B 8M 9.2M 7.45M 6.84M 12.91M 879M 13.11M 87.77M 34.45M 437M 34.56M 33.8M 1.47B
Logo DMS
Diagnostic Medical Systems (DMS) is France's leader in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: - radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; - development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine. Products and services are marketed primarily by exclusive retailers. Net sales (not including sold divisions) are distributed geographically as follows: Europe (49.6%), North and South America (17%), Asia (7.5%), Middle East (7.5%), Africa (3.1%), Oceania (1%) and other (14.3%).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-